Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05547542 · ClinicalTrials.gov registry record · Phase 1
Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing
A Phase 1 study, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT05547542 is a Phase 1 study that has completed, run by Cerevel Therapeutics. The registered enrollment target is 19 participants.
The verdict
NCT05547542, a Phase 1 study, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the target occupancy at kappa and mu opioid receptors in the brain after single oral doses of CVL-354 in healthy adult participants.
Interventions
- DRUG CVL-354
- DRUG [11C]-LY2795050
- DRUG [11C]-carfentanil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-03-02 |
| Est. Completion | 2024-08-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05547542
The ClinicalTrials.gov registry entry for NCT05547542 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerevel Therapeutics, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CVL-354 is the first listed.
NCT05547542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05547542 about?
NCT05547542 is a clinical study titled "Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing". The primary purpose of this study is to assess the target occupancy at kappa and mu opioid receptors in the brain after single oral doses of CVL-354 in healthy adult participants.
What is the current status of trial NCT05547542?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2023-03-02. Estimated completion is 2024-08-06.
What interventions are being tested in trial NCT05547542?
The interventions under investigation include: CVL-354 (DRUG), [11C]-LY2795050 (DRUG), [11C]-carfentanil (DRUG).
Who is sponsoring clinical trial NCT05547542?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.